OrbiMed Advisors
http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.
View Older Stories View More Recent Stories
-
Form 4 SpringWorks Therapeutics For: Jun 10 Filed by: ORBIMED ADVISORS LLC
-
Form 4 SpringWorks Therapeutics For: Jun 07 Filed by: ORBIMED ADVISORS LLC
-
Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
-
Xtant Medical Files $150 Million Shelf Registration Statement
-
Form SC 13G NeuroPace Inc Filed by: ORBIMED ADVISORS LLC
-
Form 4 NeuroPace Inc For: Apr 26 Filed by: ORBIMED ADVISORS LLC
-
Form 4 NeuroPace Inc For: Apr 21 Filed by: ORBIMED ADVISORS LLC
-
Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F
-
Form 4 SYNLOGIC, INC. For: Apr 20 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A SYNLOGIC, INC. Filed by: ORBIMED ADVISORS LLC
-
ITM Raises EUR 90 M (USD 109 M) to Accelerate Precision Oncology Pipeline and Support Ongoing Phase 3 Clinical Program
-
Form 3 NeuroPace Inc For: Apr 20 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G VectivBio Holding AG Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Ikena Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Edgewise Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Turning Point Therapeuti Filed by: ORBIMED ADVISORS LLC
-
Form 4 Oric Pharmaceuticals, For: Mar 29 Filed by: ORBIMED ADVISORS LLC
-
Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines
-
Form SC 13D/A SYNLOGIC, INC. Filed by: ORBIMED ADVISORS LLC
-
Crossover Health Secures $168 Million in Series D Financing to Fuel Expansion of National Primary Health Service
-
Form 4 Oric Pharmaceuticals, For: Mar 24 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A GRAYBUG VISION, INC. Filed by: ORBIMED ADVISORS LLC
-
Form 3 Edgewise Therapeutics, For: Mar 25 Filed by: ORBIMED ADVISORS LLC
-
Form 3 Ikena Oncology, Inc. For: Mar 25 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: ORBIMED ADVISORS LLC
-
Lyfebulb and CSL Behring Announce the Finalists for the 2021 Transplant Innovation Challenge
-
Form 4 Oric Pharmaceuticals, For: Mar 19 Filed by: ORBIMED ADVISORS LLC
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Fourth Quarter and Full Year 2020
-
Form SC 13D/A Oric Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form 4 Oric Pharmaceuticals, For: Mar 16 Filed by: ORBIMED ADVISORS LLC
-
Form 4 Oric Pharmaceuticals, For: Mar 11 Filed by: ORBIMED ADVISORS LLC
-
Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
-
Form SC 13D/A SpringWorks Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Form 4 SpringWorks Therapeutics For: Mar 01 Filed by: ORBIMED ADVISORS LLC
-
BlossomHill Therapeutics Closes $71M Series A Financing
-
BlossomHill Therapeutics Closes $71M Series A Financing
-
Best Penny Stocks To Buy After A Pullback? 3 To Watch Right Now
-
Form SC 13G/A Kala Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Decibel Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
-
Natera Reports Fourth Quarter and Year 2020 Financial Results
-
Form SC 13D Terns Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Gemini Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Adicet Bio, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 Adicet Bio, Inc. For: Feb 12 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form 13F-HR ORBIMED ADVISORS LLC For: Dec 31
-
Form SC 13G/A Xenon Pharmaceuticals Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G VistaGen Therapeutics, Filed by: ORBIMED ADVISORS LLC

